| 1. |
中國健康促進基金會骨質疏松防治中國白皮書編委會. 骨質疏松癥中國白皮書. 中華健康管理學雜志, 2009, 3(3): 148-154.
|
| 2. |
Cosman F, De Beur SJ, Leboff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int, 2014, 25(10): 2359-2381.
|
| 3. |
Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 1999, 282(14): 1344-1352.
|
| 4. |
Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT research group. J Clin Endocrinol Metab, 2000, 85(11): 4118-4124.
|
| 5. |
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 1999, 280(24): 2077-2082.
|
| 6. |
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausalosteoporosis. N Engl Med, 2007, 356(18): 1809-1822.
|
| 7. |
Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 2007, 22(10): 1479-1491.
|
| 8. |
Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 2014, 29(1): 1-23.
|
| 9. |
Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res, 2015, 30(5): 934-944.
|
| 10. |
Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med, 2014, 174(7): 1126-1134.
|
| 11. |
Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res, 2012, 27(2): 243-254.
|
| 12. |
Michalská D, Stepan JJ, Basson BR, et al. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab, 2006, 91(3): 870-877.
|
1/5
WeChat